Category: Industry

March 29, 2023

New advice from the World Health Organization (WHO) says healthy children and teens may not need additional COVID-19 shots, though they may need to catch up on other routine vaccines. “The public health impact of vaccinating healthy children and adolescents […]

March 28, 2023

Regeneron became one of biotech’s most valuable companies through its success making antibody drugs. Its flagship technology, a way of testing potential medicines on genetically modified mice, has helped it unearth antibody treatments for eye diseases, autoimmune conditions, rare disorders […]

March 27, 2023

4Q Revenues: €4.3 billion (-23%) 4Q Earnings: €2.3 billion (-28%) YTD Revenues: €17.3 billion (-9%) YTD Earnings: €9.3 billion (-8%) Comments: Results in the quarter and FY reflect lower demand for COVID-19 vaccines. Approximately 2 billion doses of COMIRNATY invoiced […]

March 24, 2023

The rapid demise of Silicon Valley Bank put an unwelcome spotlight on the financial position of many small biotechnology companies that relied on the storied lender. But to the people who form and build startups, SVB’s collapse is a sidebar […]

March 23, 2023

Moderna, flush with more than $18 billion in cash at the end of 2022 from revenue generated by its COVID-19 vaccine, has been reinvesting some of that money in search of its next growth engine. This year, the company is […]

March 23, 2023

There are myriad factors influencing the drug delivery market, such as the rising prevalence of chronic conditions, an ageing population, and technological advancements in drug development, leading analysts to predict continued growth in the sector at a compound annual rate […]

March 22, 2023

Can a promising new way of treating common immune diseases like psoriasis also work for disorders of the brain and nervous system? Biohaven, a biotechnology company rebooted after a 2022 sale to Pfizer, aims to find out, announcing Wednesday a […]

March 20, 2023

Gene therapy is on the rise. As clinical success, innovation and investment in this area strengthens, Precedence Research predicts that the cell and gene therapy market will grow at a CAGR of 22 percent by 2030. Additionally, the FDA expects […]

March 16, 2023

NICE has published final draft guidance regarding the recommendation of routine NHS funding for onasemnogene abeparvovec. The treatment is a potentially curative one-off gene therapy for treating a rare genetic condition, spinal muscular atrophy (SMA). It will be used specifically […]

March 16, 2023

AmplifyBio, a preclinical contract research organization (CRO), intends to build on discovery and characterization capabilities with the purchase of assets, including a site and a team of TCR-based drug development experts from PACT Pharma late last year. In a statement, […]

March 15, 2023

With this latest approval, children aged six months to four years who have completed their primary series with three doses of the companies’ original vaccine will be able to receive a 3µg booster dose of the bivalent vaccine after at […]

March 14, 2023

The panic that accompanied the collapse of the biotechnology sector’s bank of choice ebbed Sunday when the federal government moved to protect all depositors of Silicon Valley Bank. The muscular intervention allayed the fears of the many young biotech companies […]

March 13, 2023

In less than 48 hours, the bank many young biotechnology companies relied on for years was gone. On Friday, the Federal Deposit Insurance Corp. closed Silicon Valley Bank, culminating a stunning collapse that triggered alarms throughout the sector. SVB was […]

March 9, 2023

Charles River Laboratories International, Inc. has launched its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available in Research Grade (RG), High Quality […]

March 9, 2023

The partnership will see both companies advance MDX-2201 to an Investigational New Drug application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialisation. In exchange, Opko will receive an upfront payment of […]

March 7, 2023

While not surprising, the delay is a disappointment for BioMarin, which has already spent years trying to win U.S. approval of its gene therapy known as Roctavian. The company appeared on track to bring a long-lasting therapy to patients who […]

March 7, 2023

Despite having a long history in the US, the vaccines have previously only been administered via subcutaneous injection, which is given into the fatty tissue just under the skin. Now, healthcare professionals will have the option to choose to administer […]

March 7, 2023

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene and cell biotherapies in development to combat pancreatic cancer is published in the […]

March 6, 2023

Novartis is deepening ties with Voyager Therapeutics, agreeing to exercise an option to license tools the biotechnology company has developed to make gene therapies for brain diseases. The Swiss drugmaker is paying Voyager $25 million for rights to certain uses […]

March 2, 2023

Allergic reactions to the Pfizer or Moderna COVID vaccines are very rare, and a new study questions whether many of those that do occur are even real. In a small new study of 16 people who said they’d experienced an […]